Fifthly, interestingly, although our findings demonstrated that visfatin is not associated with NAFLD, the presence and severity of hepatic steatosis, liver fibrosis, lobar inflammation, NASH, and gender differences, a couple of recently published studies reported a significant association between visfatin and hepatocellular carcinoma (HCC), suggesting that visfatin plays an essential role in the proliferation of HCC cells and may also be associated with disease progression [65,66,67,68]. The gene discussed is NAMPT; the disease is Hepatic steatosis.